CellaVision ABCVLLY +12.06%69 FCF Margin % is 27.59% as of Mar. 2026, which is 76% above its 10-year median of 15.65. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 815 Medical Devices & Instruments companies, CellaVision AB ranks better than 86.38% on this metric.
The historical rank and industry rank for CellaVision AB's FCF Margin % or its related term are showing as below:
CVLLY'
s FCF Margin % Range Over the Past 10 Years
Min: 7.95 Med: 15.65 Max: 23.24
Current: 16.46
During the past 13 years, the highest FCF Margin % of CellaVision AB was 23.24%. The lowest was 7.95%. And the median was 15.65%.
CVLLY's FCF Margin % is ranked better than 86.38% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs CVLLY: 16.46
CellaVision AB FCF Margin % Related Terms
CellaVision AB FCF Margin % Historical Data
* Premium members only.
The historical data trend for CellaVision AB's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's FCF Margin % distribution charts can be found below:
* The bar in red indicates where CellaVision AB's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellaVision AB (CVLLY) has a FCF Margin % of 27.59% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CellaVision AB and its competitors. This is 76% above median its historical median of 15.65. Over the past decade, CellaVision AB's FCF Margin % has ranged from 7.95 to 23.24. According to the industry distribution chart, CellaVision AB ranks #111 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 13.6%.
Is CellaVision AB's FCF Margin % too high?
CellaVision AB's current FCF Margin % of 27.59% is 76% above median its 10-year median of 15.65. Over the past 10 years, this metric has ranged from a low of 7.95 to a high of 23.24. Based on the distribution chart, CellaVision AB ranks #111 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #111 out of 815 companies for FCF Margin %. This places CellaVision AB in the top 14% of its industry — outperforming the majority of peers. Historically, CellaVision AB's own FCF Margin % has ranged from 7.95 to 23.24 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on CellaVision AB and its competitors. CellaVision AB's current FCF Margin % is 27.59%, which is 76% above median its own 10-year median of 15.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current FCF Margin % is 27.59%, which is 76% above median its 10-year median of 15.65. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current FCF Margin % is 27.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
FCF Margin %: 27.59% (76% above median its 10-year median of 15.65)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
